Indigo offers a generalist care offer in response to the increasing demand for care and the changing playing field. Generalist care is offered by Indigo in or near the GP practice, is accessible, does not unnecessarily medicalise and is immediately accessible without waiting times. This care meets the needs of a large group of clients, who are now receiving specialist mental health care in the second line.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

RELEVATE HEALTH ACQUIRES CONNEXION360

Relevate Health | April 26, 2022

news image

Relevate Health solidifies its position as the market leader in Healthcare Professional (HCP) omnichannel engagement with the acquisition of Dallas-based ConneXion360. With this acquisition, Relevate Health now provides its omnichannel solutions and agency services to more than 185 brands from 90 pharmaceutical, biotech, and medical device manufacturers, as well as 24 hospital systems. The addition of ConneXion360 expands the Relevate Health suite of HCP engagement mar...

Read More

CURIS ANNOUNCES $30 MILLION COMMON STOCK PURCHASE AGREEMENT WITH ASPIRE CAPITAL FUND, LLC

BioSpace | February 27, 2020

news image

Curis, Inc. a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into a common stock purchase agreement (the "Agreement") of up to $30 million with Aspire Capital Fund, LLC ("Aspire Capital"). Under the terms of the Agreement, Aspire Capital has made an initial investment of $3 million via purchase of 2,693,965 common shares of Curis. In addition, Aspire Capital has committed to purchasi...

Read More

Research

VIPERGEN COLLABORATES WITH ANAVO THERAPEUTICS TO SUPPORT PHOSPHATASE-TARGETED DISCOVERY PROGRAMS

Vipergen ApS, Anavo Therapeutics | May 18, 2021

news image

Vipergen, a leading supplier of small-molecule drug discovery services focused on DNA-encoded library (DEL) technologies, has signed a drug discovery service agreement with Anavo Therapeutics. Vipergen will use its patented high-fidelity DNA-encoded library (DEL) technology platforms to provide novel small-molecule drug leads against selected Anavo discovery targets, according to the terms of the agreement. The agreement's financial terms were not disclosed. "Vipergen'...

Read More

Medical, Industry Outlook

BAYER AND BICYCLE THERAPEUTICS ENTER STRATEGIC COLLABORATION FOR DEVELOPMENT OF NOVEL TARGETED RADIONUCLIDE THERAPIES IN ONCOLOGY

Businesswire | May 11, 2023

news image

Bayer and Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics by utilizing proprietary bicyclic peptides technology (Bicycle®), announced that they have entered into a strategic collaboration agreement to discover, develop, manufacture, and commercialize Bicycle radioconjugates for multiple agreed upon oncology targets. Bicyclic peptides are peptides consisting of 9-20 amino acids that can be synthetically manufactured a...

Read More
news image

Medical

RELEVATE HEALTH ACQUIRES CONNEXION360

Relevate Health | April 26, 2022

Relevate Health solidifies its position as the market leader in Healthcare Professional (HCP) omnichannel engagement with the acquisition of Dallas-based ConneXion360. With this acquisition, Relevate Health now provides its omnichannel solutions and agency services to more than 185 brands from 90 pharmaceutical, biotech, and medical device manufacturers, as well as 24 hospital systems. The addition of ConneXion360 expands the Relevate Health suite of HCP engagement mar...

Read More
news image

CURIS ANNOUNCES $30 MILLION COMMON STOCK PURCHASE AGREEMENT WITH ASPIRE CAPITAL FUND, LLC

BioSpace | February 27, 2020

Curis, Inc. a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into a common stock purchase agreement (the "Agreement") of up to $30 million with Aspire Capital Fund, LLC ("Aspire Capital"). Under the terms of the Agreement, Aspire Capital has made an initial investment of $3 million via purchase of 2,693,965 common shares of Curis. In addition, Aspire Capital has committed to purchasi...

Read More
news image

Research

VIPERGEN COLLABORATES WITH ANAVO THERAPEUTICS TO SUPPORT PHOSPHATASE-TARGETED DISCOVERY PROGRAMS

Vipergen ApS, Anavo Therapeutics | May 18, 2021

Vipergen, a leading supplier of small-molecule drug discovery services focused on DNA-encoded library (DEL) technologies, has signed a drug discovery service agreement with Anavo Therapeutics. Vipergen will use its patented high-fidelity DNA-encoded library (DEL) technology platforms to provide novel small-molecule drug leads against selected Anavo discovery targets, according to the terms of the agreement. The agreement's financial terms were not disclosed. "Vipergen'...

Read More
news image

Medical, Industry Outlook

BAYER AND BICYCLE THERAPEUTICS ENTER STRATEGIC COLLABORATION FOR DEVELOPMENT OF NOVEL TARGETED RADIONUCLIDE THERAPIES IN ONCOLOGY

Businesswire | May 11, 2023

Bayer and Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics by utilizing proprietary bicyclic peptides technology (Bicycle®), announced that they have entered into a strategic collaboration agreement to discover, develop, manufacture, and commercialize Bicycle radioconjugates for multiple agreed upon oncology targets. Bicyclic peptides are peptides consisting of 9-20 amino acids that can be synthetically manufactured a...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us